There is definitely a market failure here, but it's not clear why.
This is why some countries have enacted laws to help with that.
https://www.statnews.com/2016/08/25/mylan-antitrust-epipen-s...
Of course that patent doesn't prevent other epinephrine autoinjectors from coming to market (and Adrenaclick is available in the US, including a couple generics).
My take is that the FDA should have some authority to deny market approval for such small improvements if the company refuses to license them to generic manufacturers. The hard part is deciding what constitutes a small improvement.
If people start to pay attention to the process and the corruption surrounding EpiPen, will it blow the lid off the entire FDA system?
"They keep trying, and the FDA keeps refusing to approve them for human use."
But corporations don't make decisions, those are made by the actual human beings that work for those corporations. Those human beings belong in prison.